Exicure Inc (XCUR)

$4.45 -0.30 (-6.32%)
Market Cap 28.36M
Revenue (ttm) 500,000.00
Net Income (ttm) -9.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,940.00%
Debt to Equity Ratio 0.00
Volume 86,800
Avg Vol 33,358
Day's Range N/A - N/A
Shares Out 6.37M
Stochastic %K 48%
Beta 4.13
Analysts Strong Buy
Price Target $2.00

Company Profile

Exicure, Inc. does not have significant operations. Previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 847 673 1700
Address:
400 Seaport Court, Suite 102, Redwood City, United States
OatesTheGoat
OatesTheGoat Mar. 20 at 1:48 PM
$XCUR 9/48 EMA cross today on the daily chart
0 · Reply
topstockalerts
topstockalerts Mar. 20 at 12:56 PM
$XCUR super thin and unpredictable. If volume hits, it can overshoot levels before anyone adjusts.
0 · Reply
hegdaom
hegdaom Mar. 19 at 10:13 PM
$XCUR New basing pattern towards 5-7 over next days for resistance
0 · Reply
kshonstocks
kshonstocks Mar. 19 at 9:49 PM
This little $XCUR interesting, trying to come out of a sort of base
1 · Reply
hegdaom
hegdaom Mar. 19 at 7:45 PM
$XCUR Very little volume will take this puppy above 9-10$ in no time.
0 · Reply
hegdaom
hegdaom Mar. 19 at 5:02 PM
$XCUR Interesting pattern brewing here. looks like above 5 soon and 6 shortly.
0 · Reply
hegdaom
hegdaom Mar. 18 at 12:01 AM
$XCUR
0 · Reply
ripztrip
ripztrip Mar. 17 at 9:47 PM
$XCUR
0 · Reply
hegdaom
hegdaom Mar. 17 at 5:55 PM
$XCUR Any upcoming catalysts?
1 · Reply
S2K_TP
S2K_TP Mar. 14 at 5:02 AM
$XCUR 5 break on watch next week
1 · Reply
Latest News on XCUR
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

Feb 5, 2026, 7:00 AM EST - 6 weeks ago

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings

Jan 21, 2026, 7:00 AM EST - 2 months ago

Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings

Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial

Dec 9, 2025, 11:39 AM EST - 3 months ago

Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial

Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting

Dec 8, 2025, 4:30 PM EST - 3 months ago

Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting

Exicure, Inc. Reports Third Quarter 2025 Financial Results

Nov 7, 2025, 4:00 PM EST - 4 months ago

Exicure, Inc. Reports Third Quarter 2025 Financial Results

New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting

Nov 3, 2025, 9:00 AM EST - 4 months ago

New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting

Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 22, 2025, 4:15 PM EDT - 5 months ago

Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Exicure Highlights Recent Achievements and Near-term Strategic Priorities

Oct 6, 2025, 7:00 AM EDT - 5 months ago

Exicure Highlights Recent Achievements and Near-term Strategic Priorities

Exicure, Inc. Reports Second Quarter 2025 Financial Results

Aug 8, 2025, 4:01 PM EDT - 8 months ago

Exicure, Inc. Reports Second Quarter 2025 Financial Results

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

Aug 4, 2025, 4:37 PM EDT - 8 months ago

Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Aug 1, 2025, 4:01 PM EDT - 8 months ago

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Exicure, Inc. Reports First Quarter 2025 Financial Results

Jun 27, 2025, 4:01 PM EDT - 9 months ago

Exicure, Inc. Reports First Quarter 2025 Financial Results

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

May 28, 2025, 4:58 PM EDT - 10 months ago

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

May 5, 2025, 8:00 AM EDT - 11 months ago

Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

Apr 14, 2025, 6:11 PM EDT - 1 year ago

Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

Apr 11, 2025, 7:42 PM EDT - 1 year ago

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

Exicure, Inc. Reports Full Year 2024 Financial Results

Mar 18, 2025, 4:01 PM EDT - 1 year ago

Exicure, Inc. Reports Full Year 2024 Financial Results

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

Mar 13, 2025, 4:08 PM EDT - 1 year ago

Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Jan 23, 2025, 12:17 AM EST - 1 year ago

CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Jan 22, 2025, 4:01 PM EST - 1 year ago

Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

Dec 26, 2024, 8:08 PM EST - 1 year ago

Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Dec 21, 2024, 1:48 PM EST - 1 year ago

CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Dec 20, 2024, 4:42 PM EST - 1 year ago

Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 4:01 PM EST - 1 year ago

Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

Sep 18, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Receives Extension from Nasdaq Hearings Panel

Exicure, Inc. Announces 1-for-5 Reverse Stock Split

Aug 26, 2024, 9:08 AM EDT - 1 year ago

Exicure, Inc. Announces 1-for-5 Reverse Stock Split

Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting

Aug 19, 2024, 10:31 AM EDT - 1 year ago

Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting

Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Aug 15, 2024, 10:31 AM EDT - 1 year ago

Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Exicure, Inc. Reports Second Quarter 2024 Financial Results

Aug 13, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Reports Second Quarter 2024 Financial Results

Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics

Aug 8, 2024, 4:27 PM EDT - 1 year ago

Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics

Exicure, Inc. Receives Positive Listing Determination from Nasdaq

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Receives Positive Listing Determination from Nasdaq

Exicure, Inc. Reports First Quarter 2024 Financial Results

Jun 17, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Reports First Quarter 2024 Financial Results

Exicure, Inc. Reports Full Year 2023 Financial Results

Jun 6, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Reports Full Year 2023 Financial Results

Exicure, Inc. Received Nasdaq Notice of a Delisting Determination

May 23, 2024, 4:01 PM EDT - 1 year ago

Exicure, Inc. Received Nasdaq Notice of a Delisting Determination

Exicure, Inc. Reports Third Quarter 2023 Financial Results

May 16, 2024, 4:08 PM EDT - 2 years ago

Exicure, Inc. Reports Third Quarter 2023 Financial Results

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K

Apr 22, 2024, 4:01 PM EDT - 2 years ago

Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

Feb 5, 2024, 4:01 PM EST - 2 years ago

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

Aug 23, 2023, 9:48 AM EDT - 2 years ago

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 11, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

Jul 14, 2023, 4:01 PM EDT - 2 years ago

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives

May 26, 2023, 4:01 PM EDT - 3 years ago

Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives

Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld

May 4, 2023, 4:01 PM EDT - 3 years ago

Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld

Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 27, 2023, 4:01 PM EDT - 3 years ago

Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update

Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors

Feb 24, 2023, 5:10 PM EST - 3 years ago

Exicure, Inc. Announces Closing of Private Placement Transaction with CBI USA, Inc. and Changes to the Board of Directors

Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements

Dec 14, 2022, 5:00 AM EST - 3 years ago

Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements

Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 14, 2022, 4:01 PM EST - 3 years ago

Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives

Sep 26, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives

Exicure Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference

Sep 1, 2022, 7:00 AM EDT - 3 years ago

Exicure Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference

Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress

Aug 15, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress

Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 20, 2022, 4:01 PM EDT - 3 years ago

Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

OatesTheGoat
OatesTheGoat Mar. 20 at 1:48 PM
$XCUR 9/48 EMA cross today on the daily chart
0 · Reply
topstockalerts
topstockalerts Mar. 20 at 12:56 PM
$XCUR super thin and unpredictable. If volume hits, it can overshoot levels before anyone adjusts.
0 · Reply
hegdaom
hegdaom Mar. 19 at 10:13 PM
$XCUR New basing pattern towards 5-7 over next days for resistance
0 · Reply
kshonstocks
kshonstocks Mar. 19 at 9:49 PM
This little $XCUR interesting, trying to come out of a sort of base
1 · Reply
hegdaom
hegdaom Mar. 19 at 7:45 PM
$XCUR Very little volume will take this puppy above 9-10$ in no time.
0 · Reply
hegdaom
hegdaom Mar. 19 at 5:02 PM
$XCUR Interesting pattern brewing here. looks like above 5 soon and 6 shortly.
0 · Reply
hegdaom
hegdaom Mar. 18 at 12:01 AM
$XCUR
0 · Reply
ripztrip
ripztrip Mar. 17 at 9:47 PM
$XCUR
0 · Reply
hegdaom
hegdaom Mar. 17 at 5:55 PM
$XCUR Any upcoming catalysts?
1 · Reply
S2K_TP
S2K_TP Mar. 14 at 5:02 AM
$XCUR 5 break on watch next week
1 · Reply
ReversalTrack
ReversalTrack Mar. 8 at 5:28 AM
$XCUR As of March 8, 2026, Exicure, Inc. ($XCUR) is showing signs of high-volatility momentum following a major leadership overhaul and positive clinical data updates.
0 · Reply
cfvk
cfvk Mar. 7 at 8:22 AM
$XCUR holding 3.55-3.7 interesting
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 21 at 4:19 PM
$XCUR Current Stock Price: $3.60
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 20 at 11:27 PM
$XCUR RSI: 37.04, MACD: -0.4457 Vol: 0.56, MA20: 4.24, MA50: 5.27 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
CapitalContinuum
CapitalContinuum Feb. 17 at 1:06 PM
$XCUR Pre-revenue biotech; early-stage.
0 · Reply
stalkerjude
stalkerjude Feb. 17 at 8:36 AM
$XCUR Pre-revenue biotech; early-stage
0 · Reply
SystemicStonks
SystemicStonks Feb. 9 at 3:13 PM
$XCUR Digital health or curations platform; user adoption is unproven.
0 · Reply
BioTuesdays
BioTuesdays Feb. 6 at 3:46 PM
$XCUR announced that Annals of Hematology has published results from a Phase 2 clinical study demonstrating rapid stem cell mobilization with burixafor (GPC-100/TG-0054)—a highly selective CXCR4 inhibitor—in patients with multiple myeloma and lymphoma undergoing transplant https://biotuesdays.com/2026/02/06/exicure-reports-publication-highlighting-phase-2-burixafor-data-showing-rapid-stem-cell-mobilization/
1 · Reply
DARKP00L
DARKP00L Feb. 5 at 12:16 PM
$XCUR 07:14 on Feb. 05 2026 Exicure Announces Annals Of Hematology Publication Showing Burixafor Plus G-CSF Rapid Stem Cell Mobilization In Multiple Myeloma And Lymphoma Transplant Patients #tradeideas
0 · Reply
G101SPM
G101SPM Feb. 4 at 8:38 PM
#SHOWTIME ASTCT and CIBMTR Tandem Meeting (February 5) Scheduled to appear: $ACLX, $ADPT, $ARTV, $XCUR Americas Committee for Treatment and Research in Multiple Sclerosis Forum (February 5-6) Scheduled to appear: $TGTX
0 · Reply
ook__
ook__ Feb. 3 at 12:17 AM
$XCUR to the moon
0 · Reply